Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs

Proteins often have both orthosteric and allosteric binding sites. Endogenous ligands, such as hormones and neurotransmitters, bind to the orthosteric site, while synthetic ligands may bind to orthosteric or allosteric sites, which has become a focal point in drug discovery. Usually, such allosteric modulators bind to a protein noncompetitively with its endogenous ligand or substrate. The growing interest in allosteric modulators has resulted in a substantial increase of these entities and their features such as binding data in chemical libraries and databases. Although this data surge fuels research focused on allosteric modulators, binding data is unfortunately not always clearly indicated as being allosteric or orthosteric. Therefore, allosteric binding data is difficult to retrieve from databases that contain a mixture of allosteric and orthosteric compounds. This decreases model performance when statistical methods, such as machine learning models, are applied. In previous work we generated an allosteric data subset of ChEMBL release 14. In the current study an improved text mining approach is used to retrieve the allosteric and orthosteric binding types from the literature in ChEMBL release 22. Moreover, convolutional deep neural networks were constructed to predict the binding types of compounds for class A G protein-coupled receptors (GPCRs). Temporal split validation showed the model predictiveness with Matthews correlation coefficient (MCC) = 0.54, sensitivity allosteric = 0.54, and sensitivity orthosteric = 0.94. Finally, this study shows that the inclusion of accurate binding types increases binding predictions by including them as descriptor (MCC = 0.27 improved to MCC = 0.34; validated for class A GPCRs, trained on all GPCRs). Although the focus of this study is mainly on class A GPCRs, binding types for all protein classes in ChEMBL were obtained and explored. The data set is included as a supplement to this study, allowing the reader to select the compounds and binding types of interest.

[1]  Naomi R. Latorraca,et al.  Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure , 2017, Nature.

[2]  E. Novellino,et al.  Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. , 2008, Bioorganic & medicinal chemistry.

[3]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[4]  Ruben Abagyan,et al.  Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists , 2016, Nature.

[5]  Shifan Ma,et al.  Prediction of Orthosteric and Allosteric Regulations on Cannabinoid Receptors Using Supervised Machine Learning Classifiers. , 2019, Molecular pharmaceutics.

[6]  Shuai Li,et al.  ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks , 2015, Nucleic Acids Res..

[7]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[8]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[9]  Patrik Johansson,et al.  Structural insight into allosteric modulation of protease-activated receptor 2 , 2017, Nature.

[10]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[11]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[12]  Willem Soudijn,et al.  Allosteric modulation of G protein-coupled receptors: perspectives and recent developments. , 2004, Drug discovery today.

[13]  Jing Lu,et al.  Are there physicochemical differences between allosteric and competitive ligands? , 2017, PLoS Comput. Biol..

[14]  Anthony Ivetac,et al.  High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 , 2014, Nature.

[15]  Gerard J. P. van Westen,et al.  Identification of novel small molecule inhibitors for solute carrier SGLT1 using proteochemometric modeling , 2019, Journal of Cheminformatics.

[16]  Bryan L. Roth,et al.  Molecular control of δ-opioid receptor signalling , 2014, Nature.

[17]  Gerard J. P. van Westen,et al.  Chemical, Target, and Bioactive Properties of Allosteric Modulation , 2014, PLoS Comput. Biol..

[18]  George Papadatos,et al.  The ChEMBL database in 2017 , 2016, Nucleic Acids Res..

[19]  Steven M. Moss,et al.  Structure of the human P2Y12 receptor in complex with an antithrombotic drug , 2014, Nature.

[20]  K. Chung,et al.  Orthosteric and allosteric action of the C5a receptor antagonists , 2018, Nature Structural & Molecular Biology.

[21]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[22]  Ali Jazayeri,et al.  Intracellular allosteric antagonism of the CCR9 receptor , 2016, Nature.

[23]  M. Congreve,et al.  Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. , 2017, Trends in pharmacological sciences.

[24]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[25]  M. Liang,et al.  Serial millisecond crystallography for routine room-temperature structure determination at synchrotrons , 2017, Nature Communications.

[26]  Jens Meiler,et al.  Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.

[27]  George Papadatos,et al.  Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set , 2017, bioRxiv.

[28]  Robert P. Sheridan,et al.  Time-Split Cross-Validation as a Method for Estimating the Goodness of Prospective Prediction , 2013, J. Chem. Inf. Model..

[29]  Hualiang Jiang,et al.  Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex , 2013, Science.

[30]  Sujata Sharma,et al.  Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40 , 2017, Nature Structural &Molecular Biology.

[31]  Shaoyong Lu,et al.  Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions. , 2018, Journal of medicinal chemistry.

[32]  R. Sakai,et al.  Ligands for ionotropic glutamate receptors. , 2009, Progress in molecular and subcellular biology.